Comparison of @entity396 and @entity4444 in the treatment of XXXX .

@entity4444 @entity1 @entity167 @entity1066 @entity396 @entity5834 @entity5015 @entity2275
The efficacy of @entity396 (a synthetic analogue of @entity5015 ) and @entity4444 in the treatment of @entity2275 was evaluated. Thirty-two @entity1 with endoscopically proven @entity2275 were randomized, in a double-blind manner, in one of three groups that received four daily doses of either @entity396 , 50 or 200 micrograms, or @entity4444 , 300 mg. @entity1066 healing was assessed endoscopically after 4 weeks of treatment. The three groups were fairly comparable in their @entity167 and @entity5834 intake, previous @entity1066 history and @entity1066 size. A relatively high proportion of @entity1 in the @entity4444 -treated group was smokers. Only one @entity1 was withdrawn from the study. On the @entity396 low dose, healing of the @entity1066 was observed in 20% of the @entity1 . In contrast, healing on the high dose of @entity396 (70%) was not significantly different from that on @entity4444 (73%). No important clinical side effects were observed in any of the @entity1 . These results (part of a multicenter, international study) suggest that the divided daily dose of 800 micrograms @entity396 is safe and effective in the short-term treatment of @entity2275 .
